What DaAn Gene does

DaAn Gene (Guangzhou Da An Gene Co., Ltd.) is a state-owned, publicly listed Chinese in vitro diagnostics (IVD) company headquartered in Guangzhou that develops, manufactures, and sells clinical diagnostic reagents, instruments, and consumables through a direct sales motion to hospitals, disease control centers, blood stations, and third-party testing institutions. The company was among China's first batch of high-tech IVD enterprises and listed on the Shenzhen Stock Exchange (SZ002030) in 2004. Its foundational technology is fluorescent PCR-based nucleic acid detection, but the platform portfolio has expanded to encompass molecular diagnostics, chemiluminescence immunoassay, biochemistry, immunofluorescence, mass spectrometry (LC-MS/MS and TOF), pathology, flow cytometry, and sequencing. Product lines include automated total laboratory automation lines (Stream DAlas8000 TLA), fully automatic nucleic acid detection analyzers (Stream Insight96), nucleic acid extraction instruments (Smart32, Ballet X3), clinical chemistry analyzers, the DAC 120 chemiluminescence analyzer, POCT devices, and the NMPA-approved DAseq-60 small gene sequencer, plus a reagent catalog covering infectious diseases (HBV, HIV, monkeypox, chikungunya, Nipah, RSV, pertussis, influenza), respiratory pathogens, genetic testing (hereditary deafness), and pharmacogenomics (ALDH2, MTHFR).

The business model is sales-led with a one-time equipment/reagent/license sale structure to medical institutions; pricing is not publicly disclosed. The company participates in major IVD industry conferences (CMEF, CACLP, NCLM, CCDLM) and conducts academic enablement activities to support mid- and bottom-funnel conversion. As of 2025, DaAn Gene employs 1,334 personnel, has completed 67 national and provincial-level key research projects, and ships products to 140+ countries. Recent strategic priorities include first-in-China NMPA approvals in infectious disease diagnostics (chikungunya, monkeypox, HIV-1 dual), entry into the chemiluminescence market, expansion into Medical SPD supply chain services, and deepened public health partnerships with Guangzhou CDC, Sun Yat-sen University, and Guangzhou National Laboratory. The company is currently positioned in a post-COVID normalization phase, with new product launches offsetting legacy revenue compression observed across the Chinese A-share IVD sector.

Name

DaAn Gene

Legal name

广州达安基因股份有限公司

Website

https://daangene.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

DaAn Gene (SZ002030) is a Guangzhou-based, state-owned Chinese IVD company that develops and sells fluorescent PCR diagnostic reagents, automated instruments, and clinical testing consumables to hospitals, CDCs, and blood stations across China and 140+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. 体外诊断试剂、仪器和配套耗材销售: DaAn Gene generates revenue through the development, production, and sales of clinical examination reagents, instruments, and supporting consumables. The company operates as a listed company on the Shenzhen Stock Exchange (SZ002030).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

DaAn Gene develops, manufactures, and sells molecular diagnostic products, with a core focus on fluorescent PCR-based diagnostic reagent kits for clinical disease detection, infectious disease screening, and public health monitoring. The company also produces supporting diagnostic instruments (e.g., automated nucleic acid detection systems, chemiluminescence, and gene chip platforms) and consumables used by medical laboratories, hospitals, and disease control centers.

Product overview

DaAn Gene is a state-owned biotechnology enterprise specializing in fluorescent PCR diagnostic reagents, instruments, and comprehensive in vitro diagnostics solutions. The company operates a multi-platform portfolio comprising molecular diagnostics (fluorescent PCR), chemiluminescence immunoassay, biochemistry, immunofluorescence, mass spectrometry (LC-MS/MS and TOF), pathology, and flow cytometry platforms. The product ecosystem includes high-throughput automated systems (Stream DAlas8000 TLA, Stream Insight96), nucleic acid extraction instruments (Smart32 series, Ballet X3), clinical chemistry analyzers (2000/800 speed), chemiluminescence analyzers (DAC 120), POCT devices (Himo series), and over 140 types of reagents covering infectious diseases (hepatitis, HIV, monkeypox, chikungunya, nipah virus, RSV, pertussis), respiratory pathogens, genetic testing (hereditary deafness), pharmacogenomics (ALDH2, MTHFR), and tumor markers. The company also provides sequencing solutions including the DAseq-60 small gene sequencer. Products are distributed to global markets and the company is listed on Shenzhen Stock Exchange (stock code: SZ002030).

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Products shipped to 140+ countries and regions worldwide
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Guangzhou CDC (广州市疾控中心)coreStrategic or Co-development PartnerStrategic cooperation with Guangzhou CDC and Sun Yat-sen University for public health monitoring and disease control capabilities.
• Sun Yat-sen UniversitycoreStrategic or Co-development PartnerTrilateral strategic cooperation with Guangzhou CDC and DaAn Gene for pathogen detection and public health research.
• Guangzhou National LaboratorycoreStrategic or Co-development Partner产学研落地转化 (industry-academia-research transformation) partner for DAseq-60 sequencing instrument development and commercialization.
• Saijun Biology (赛隽生物)minorOthersInvested company contributing to stem cell therapy clinical application for liver failure treatment in Guangzhou Nansha.
• Zhongshan DaAn Gene Biotechnology Co., Ltd. (中山市达安基因生物科技有限公司)coreTechnology or IntegrationSubsidiary company that developed Nipah virus nucleic acid detection kit for border health quarantine and disease control.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Hologic: Hologic is a US-based diagnostics and medical imaging company with strong molecular diagnostics (Panther system) and women's health franchises. It is an international incumbent comparable to DaAn Gene's molecular diagnostics and infectious disease testing business.
• QIAGEN: QIAGEN is a global sample-prep and molecular diagnostics company offering PCR reagents, extraction systems, and NGS workflows. Comparable to DaAn Gene's nucleic acid extraction (Smart32/Ballet X3) and fluorescent PCR reagents, especially in international markets where DaAn's products are distributed.
• bioMérieux / BioFire: bioMérieux (through BioFire) is a global leader in syndromic molecular testing (FilmArray panels), directly comparable to DaAn Gene's respiratory 6+2 panel and other multiplex infectious disease solutions.
• Mindray: Mindray (迈瑞医疗) is China's largest medical device and IVD company, with broad offerings in chemistry, immunoassay, hematology, and molecular diagnostics. As a multi-national incumbent, it competes with DaAn Gene across multiple platforms including biochemistry and immunoassay.

Direct peers

• Sansure Biotech: Sansure Biotech (圣湘生物) is a Chinese molecular diagnostics company with a similar focus on fluorescent PCR reagents for infectious diseases (hepatitis, HIV, respiratory pathogens). It directly competes with DaAn Gene in Chinese hospital and CDC accounts across overlapping test menus.
• BGI Genomics: BGI Genomics (华大基因) is a leading Chinese molecular diagnostics and sequencing company with overlapping PCR, NIPT, mNGS, and infectious disease products. It competes with DaAn Gene across sequencing-based testing (vs. DAseq-60) and traditional molecular diagnostics reagents.
• Cepheid (Danaher): Cepheid, a Danaher subsidiary, operates the GeneXpert platform, the global leader in molecular POCT for infectious diseases. It serves as the international benchmark for DaAn Gene's molecular POCT and respiratory pathogen testing products.
• Autobio Diagnostics: Autobio Diagnostics (安图生物) is a Chinese IVD company specializing in chemiluminescence immunoassay and microbiology, with growing molecular diagnostics. It competes with DaAn Gene's chemiluminescence (DAC120) and infectious disease reagent offerings in Chinese hospitals.
• Snibe (Shenzhen New Industries Biomedical Engineering): Snibe (新产业生物) is one of China's leading chemiluminescence immunoassay specialists, a direct competitor in DaAn Gene's DAC120 and broader CLIA segment with similar hospital-focused reagent menus.

Regional players

• KingMed Diagnostics: KingMed Diagnostics (金域医学) is China's largest third-party medical laboratory chain. While primarily a clinical testing service provider rather than a kit manufacturer, it is a major buyer of molecular diagnostics reagents and competes for infectious disease and genetic testing volumes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DaAn Gene